Selective Glucocorticoid Receptor Modulators (SEGRAMs): Can They Improve the Therapeutic Index of Steroid Therapy?

Abstract

Glucocorticoids remain indispensable anti-inflammatory drugs across a wide range of inflammatory and immune-mediated diseases, but their long-term use is limited by cumulative toxicity. Attempts to develop safer steroids gave rise to selective glucocorticoid receptor agonists and modulators (SEGRAMs), initially based on the premise that anti-inflammatory efficacy might be preserved while signaling linked to adverse effects was reduced. Current glucocorticoid receptor biology no longer supports such a simple binary model. Glucocorticoid receptor output is shaped by ligand-induced conformation, DNA sequence, chromatin accessibility, cofactor recruitment, and cell-specific transcriptional context, making selective modulation a context-dependent pharmacologic phenomenon rather than a fixed molecular property. In this clinically oriented narrative review, we reassess the SEGRAMs concept from receptor biology to translational and early clinical evidence, with explicit distinction between mechanistic dissociation, translational separation of efficacy from selected toxicities, and clinically meaningful improvement in the therapeutic index. Representative compounds have shown that selective glucocorticoid receptor modulation is pharmacologically feasible and, in some settings, may separate anti-inflammatory activity from selected steroid-related liabilities. However, the available evidence also indicates that any potential advantage is disease-specific, toxicity-specific, and exposure-dependent, and that mechanistic dissociation does not by itself justify therapeutic claims, particularly in the absence of long-term comparative outcome data. The most credible future for SEGRAMs lies not in universal replacement of conventional glucocorticoids, but in their potential to improve the therapeutic index in diseases for which prolonged or repeated glucocorticoid exposure remains necessary, but in which cumulative harm from toxicity is a major treatment burden.